The American Association for Cancer Research (AACR) meeting in April was a big event for Merck & Co. Inc., as the company's combination of Keytruda (pembrolizumab) with chemotherapy outshone rival combinations from Bristol-Myers Squibb Co. and Roche in first-line, metastatic non-small cell lung cancer.
Merck's combination received accelerated approval from the US FDA in May 2017, and Keytruda has also been approved as a monotherapy in first-line NSCLC with at least 50% PD-L1 expression since October 2016. (Also see "It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer" - Scrip, 25 October, 2016.) The company recently announced that Keytruda monotherapy was shown to work at all levels of expression in the KEYNOTE-042 study, which promises to solidify its grip on the indication
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?